4536 SANTEN PHARMACEUTICAL CO.,LTD. - Financial Results

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

4536

TSE Prime

SANTEN PHARMACEUTICAL CO.,LTD.

1,553.0

JPY

+8.5

(+0.55%)

Dec 23, 3:30 pm JST

9.91

USD

Dec 23, 1:30 am EST

Result

PTS

outside of trading hours

1,553

Dec 23, 8:33 pm JST

Summary Chart Historical News Financial Result

Current Period Guidance

Annual

Result

Guidance History

Growth Rate

Profitability

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2021	249,605	12,187	11,688	9,311	23.3	28	May 11, 2021	IFRS
Mar, 2022	266,257	35,886	35,616	27,218	68.1	32	May 10, 2022	IFRS
Mar, 2023	279,037	-3,090	-5,799	-14,948	-38.6	32	May 11, 2023	IFRS
Mar, 2024	301,965	38,541	29,874	26,642	72.6	33	May 9, 2024	IFRS
Mar, 2025 Guidance	302,000	44,500	45,000	32,500	95.2	34	Nov 7, 2024	IFRS
YoY	+0.0%	+15.5%	+50.6%	+22.0%	+31.2%

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
Mar, 2020	May 9, 2019	248,000	34,500	34,300	23,200	26	IFRS
	Nov 6, 2019	248,000	34,500	34,300	23,200	27	IFRS
Results	May 8, 2020	241,555	33,535	32,091	23,618	27	IFRS
Mar, 2021	May 8, 2020	Available in future release
	Apr 9, 2021
Results	May 11, 2021
Mar, 2022	May 11, 2021
Results	May 10, 2022
Mar, 2023	May 10, 2022
	Aug 4, 2022
	Nov 8, 2022
	Feb 7, 2023
	Apr 27, 2023
Results	May 11, 2023
Mar, 2024	May 11, 2023
	Sep 20, 2023
	Nov 7, 2023
	Feb 8, 2024
Results	May 9, 2024
Mar, 2025	May 9, 2024	297,000	44,500	45,000	ー	34	IFRS
-	Aug 6, 2024	302,000	44,500	45,000	ー	34	IFRS
-	Nov 7, 2024	302,000	44,500	45,000	32,500	34	IFRS

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Mar, 2000	83,577	+4.9	Available in future release
Mar, 2001	88,448	+5.8
Mar, 2002	88,966	+0.6
Mar, 2003	90,252	+1.4
Mar, 2004	89,857	-0.4
Mar, 2005	92,696	+3.2
Mar, 2006	98,397	+6.2
Mar, 2007	100,485	+2.1
Mar, 2008	103,394	+2.9
Mar, 2009	101,618	-1.7
Mar, 2010	110,594	+8.8
Mar, 2011	110,812	+0.2
Mar, 2012	114,416	+3.3
Mar, 2013	119,066	+4.1
Mar, 2014	146,260	+22.8
Mar, 2015	161,831	+10.6
Mar, 2016	195,291	+20.7
Mar, 2017	199,096	+1.9
Mar, 2018	224,942	+13.0
Mar, 2019	234,026	+4.0
Mar, 2020	241,555	+3.2
Mar, 2021	249,605	+3.3
Mar, 2022	266,257	+6.7
Mar, 2023	279,037	+4.8
Mar, 2024	301,965	+8.2
Mar, 2025 Guidance	302,000	0.0	44,500	+15.5	45,000	+50.6	95.2	+31.1

Fiscal Year	Revenue	Operating Profit	Operating Profit Margin	ROE	ROA	Total Asset Turnover Ratio	Adj. EPS
Mar, 2023	279,037	-3,090	-1.1	-4.73	-3.39	0.63	-38.6
Mar, 2024	301,965	38,541	12.8	8.88	6.22	0.70	72.6
Mar, 2025 Guidance	302,000	44,500	14.7	11.25	7.94	0.74	95.2

All-Time High

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	301,965	80,180	79,470	53,373	129.0
Fiscal Year	Mar, 2024	Mar, 2016	Mar, 2016	Mar, 2016	Mar, 2016

Second Half

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Oct - Mar, 2021	137,498	17,081	17,223	12,911	32.3	16	May 10, 2022	IFRS
Oct - Mar, 2022	150,122	15,931	13,304	7,093	18.3	16	May 11, 2023	IFRS
Oct - Mar, 2023	156,159	13,442	5,799	7,362	20.1	17	May 9, 2024	IFRS
Oct - Mar, 2024 Guidance	155,596	20,627	21,161	13,728	40.2	17	Nov 7, 2024	IFRS
YoY	-0.4%	+53.5%	+264.9%	+86.5%	+100.5%

Cash Flow

Annual

Fiscal Year	Operating Profit	Fee Cash Flow	Operating Cash Flow	Investing Cash Flow	Financial Cash Flow	Cash & Equivalents	Cash Ratio	Accounting Standards
Mar, 2022	35,886	10,874	46,043	-35,169	5,557	83,014	18.05	IFRS
Mar, 2023	-3,090	10,370	37,147	-26,777	-37,220	57,903	13.75	IFRS
Mar, 2024	38,541	66,504	72,649	-6,145	-34,031	94,582	21.71	IFRS

Actual Performance and Financial Trends

Accumulated Results 2nd Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Apr - Sep, 2022	128,915	-19,021	-19,103	-22,041	-56.1	ー	Nov 8, 2022	IFRS
Apr - Sep, 2023	145,806	25,099	24,075	19,280	52.1	80.6	Nov 7, 2023	IFRS
Apr - Sep, 2024	146,404	23,873	23,839	18,772	52.9	53.0	Nov 7, 2024	IFRS
YoY	+0.4%	-4.9%	-1.0%	-2.6%	+1.6%

Quarterly Results

Result

Growth Rate

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Oct - Dec, 2022	70,871	8,874	7,510	5,977	15.3	12.5	Feb 7, 2023	IFRS
Jan - Mar, 2023	79,251	7,057	5,794	1,116	2.9	8.9	May 11, 2023	IFRS
Apr - Jun, 2023	72,389	12,750	12,868	10,414	27.9	17.6	Aug 3, 2023	IFRS
Jul - Sep, 2023	73,417	12,349	11,207	8,866	23.9	16.8	Nov 7, 2023	IFRS
Oct - Dec, 2023	77,027	11,058	9,484	7,333	19.9	14.4	Feb 8, 2024	IFRS
Jan - Mar, 2024	79,132	2,384	-3,685	29	0.1	3.0	May 9, 2024	IFRS
Apr - Jun, 2024	74,771	13,155	13,450	10,633	29.6	17.6	Aug 6, 2024	IFRS
Jul - Sep, 2024	71,633	10,718	10,389	8,139	22.9	15.0	Nov 7, 2024	IFRS
YoY	-2.4%	-13.2%	-7.3%	-8.2%	-4.2%

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Oct - Dec, 2019	63,551	+8.0	Available in future release
Jan - Mar, 2020	59,229	-2.6
Apr - Jun, 2020	57,563	-2.7
Jul - Sep, 2020	61,342	+2.9
Oct - Dec, 2020	62,881	-1.1
Jan - Mar, 2021	67,819	+14.5
Apr - Jun, 2021	64,986	+12.9
Jul - Sep, 2021	63,773	+4.0
Oct - Dec, 2021	67,042	+6.6
Jan - Mar, 2022	70,456	+3.9
Apr - Jun, 2022	65,533	+0.8
Jul - Sep, 2022	63,382	-0.6
Oct - Dec, 2022	70,871	+5.7
Jan - Mar, 2023	79,251	+12.5
Apr - Jun, 2023	72,389	+10.5
Jul - Sep, 2023	73,417	+15.8
Oct - Dec, 2023	77,027	+8.7
Jan - Mar, 2024	79,132	-0.2
Apr - Jun, 2024	74,771	+3.3
Jul - Sep, 2024	71,633	-2.4	10,718	-13.2	10,389	-7.3	22.9	-4.2

All-Time High Quarterly Results

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	79,251	54,586	54,109	36,116	87.3
Fiscal Year	Mar, 2023	Sep, 2015	Sep, 2015	Sep, 2015	Sep, 2015

Key Balance Sheet Figures

Fiscal Year	BPS	Equity Ratio	Total Asset	Equity	Retained Earnings	Interest-Bearing Debt Ratio	Announce	Accounting Standards
Mar, 2022	843.60	73.4	459,976	337,488	290,477	ー	May 10, 2022	IFRS
Mar, 2023	783.30	69.8	421,179	293,979	238,071	ー	May 11, 2023	IFRS
Mar, 2024	843.24	70.2	435,699	306,055	240,029	ー	May 9, 2024	IFRS
Apr - Sep, 2024	828.34	70.6	409,085	288,977	252,938	ー	Nov 7, 2024	IFRS

SANTEN PHARMACEUTICAL CO.,LTD.(4536) Financial Results